红花牌品牌怎么样 申请店铺

我要投票 红花牌在生发行业中的票数:714 更新时间:2026-02-07
红花牌是哪个国家的品牌?「红花牌」是 天津宏仁堂药业有限公司 旗下著名品牌。该品牌发源于天津,由创始人张彦森在1980期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力红花牌品牌出海!将品牌入驻外推网,定制红花牌品牌推广信息,可以显著提高红花牌产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

红花牌怎么样

天津宏仁堂药业有限公司始建于1923年,是由乐家老铺(北京同仁堂)第13代传人乐笃周先生所创建。

公司产品以面散剂为传统、胶囊剂为特色涉及内、外、妇、儿、皮肤、五官等科室,注册商标为“红花牌”。产品覆盖到我国二十多个省市自治区,部分产品已打入国际市场。主要产品有脑灵素、血府逐瘀胶囊、养血生发胶囊、白癜风胶囊、冠心苏合胶囊、紫雪等56个中药精品。

如今的宏仁堂已正式更名为“天津宏仁堂药业有限公司”,并改制为以天津市医药集团有限公司、天津同仁堂集团股份有限公司为投资主体的多元化现代企业,注册商标“红花牌”,为驰名保护。

面对激烈的市场竞争和中药现代化步伐的加快,企业始终秉持“修合虽无人见,存心自有天知”的古训和药德思想,贯彻“为客户实现价值,为员工提供机会,为社会承担责任”的企业宗旨,以“矢志不渝、锐意创新、忠诚营销、共享繁荣”的经营理念,全面贯彻实施大品种战略。紧紧围绕拳头产品“血府逐瘀胶囊”,构建了以血府逐瘀胶囊、养血生发胶囊、冠心苏和胶囊、白癜风胶囊为支撑的大品种群,每年以两位数的年经济增长速度,带动企业向规模经济发展。

吃水不忘挖井人,如此成绩的取得自然离不开历代红花人辛勤的汗水和艰苦创业、拼搏进取的精神。回首企业90年的艰辛历程,从乐笃周先生满怀热情创建宏仁堂,到今天走在我国中医药产业中,享有举足轻重的地位的天津宏仁堂药业有限公司;从最初几十人前店后厂式的作坊,到目前拥有日益壮大的科技,营销,生产,检验等高水平,高素质的员工队伍及先进的全自动生产设备和检验仪器。人均利税创同行业最高水平的大中型企业,实现了跨越式发展。企业不仅成功研制胶囊剂型,成为该剂型的发源地,而且拓宽了研发药品的范围,将传统医学与现代技术完美结合,涉及内、外、妇、儿、皮肤、五官等各科,培育出54个中药精品。其中,红花牌“血府逐瘀胶囊”依靠过硬的质量及疗效,通过科学营销手段,产品在全国医患者中享有广泛影响力,已形成相当规模,被列入天津市医药集团重点发展品种。1994年天津宏仁堂药业有限公司还被国家内贸部正式授予“中华老字号”荣誉称号。天津宏仁堂药业有限公司,站在赛达新园区,宏仁堂再次跨入了崭新的发展历程,为自己未来在新园区的全速起航描绘了新的画卷,为弘扬祖国医药文化再创辉煌!

Tianjin hongrentang Pharmaceutical Co., Ltd. was founded in 1923 by Mr. Le Duzhou, the 13th generation successor of lejialaopu (Beijing Tongrentang). The company's products are characterized by traditional powder and capsule, involving internal, external, women, children, skin, facial features and other departments, with the registered trademark of "Honghua brand". The products cover more than 20 provinces and autonomous regions in China, and some of them have entered the international market. The main products are Naolingsu, Xuefu Zhuyu Capsule, Yangxue Shengfa capsule, vitiligo capsule, Guanxinsuhe capsule, Zixue and other 56 excellent traditional Chinese medicine products. Now, hongrentang has officially changed its name to "Tianjin hongrentang Pharmaceutical Co., Ltd." and has been transformed into a diversified modern enterprise with Tianjin Pharmaceutical Group Co., Ltd. and Tianjin Tongrentang Group Co., Ltd. as the main investors, with the registered trademark of "honghuapai" for well-known protection. In the face of the fierce market competition and the acceleration of the modernization of traditional Chinese medicine, the enterprise always adheres to the ancient motto and medical ethics of "no one can see the repair, but the enterprise has a natural knowledge", implements the enterprise tenet of "realizing value for customers, providing opportunities for employees, and taking responsibility for the society", and comprehensively implements the business philosophy of "unswerving, determined innovation, loyal marketing, sharing and prosperity" Implement the strategy of large variety. Focusing on the key product "Xuefu Zhuyu Capsule", a large variety group supported by Xuefu Zhuyu Capsule, Yangxue Shengfa capsule, Guanxinsuhe capsule and vitiligo capsule has been established. With a double-digit annual economic growth rate every year, the company is driven to develop into a scale economy. Draught does not forget to dig wells, such achievements can not be achieved without the hard work of generations of Honghua people and the spirit of hard work, hard work and enterprising. Looking back on the 90 years of hard work of the enterprise, from Mr. leduzhou's enthusiastic creation of hongrentang to today's Tianjin hongrentang Pharmaceutical Co., Ltd., which plays an important role in China's traditional Chinese medicine industry; from the first dozens of factory style workshops in front of the store, to the present day, it has a growing number of high-level, high-quality staff and advanced technology, marketing, production, testing, etc Automatic production equipment and inspection instruments. The per capita profits and taxes have reached the highest level of large and medium-sized enterprises in the same industry, realizing leapfrog development. The enterprise has not only successfully developed the capsule dosage form and become the birthplace of the dosage form, but also broadened the scope of drug research and development, perfectly combined traditional medicine with modern technology, involving internal, external, women, children, skin, facial features and other branches, and cultivated 54 excellent traditional Chinese medicine products. Among them, Honghua brand "Xuefu Zhuyu Capsule" relies on excellent quality and curative effect, through scientific marketing means, the product enjoys wide influence in the national medical patients, has formed a considerable scale, and has been listed in the key development varieties of Tianjin Pharmaceutical Group. In 1994, Tianjin hongrentang Pharmaceutical Co., Ltd. was officially awarded the honorary title of "China time honored brand" by the Ministry of internal trade. Tianjin hongrentang Pharmaceutical Co., Ltd. is standing in Saida new park. Hongrentang has once again stepped into a new development process. It has described a new picture for its full speed sailing in the new park in the future, and created another brilliant future for promoting the pharmaceutical culture of the motherland!

本文链接: https://brand.waitui.com/f66b27803.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

央行等八部门:在境内开展现实世界资产代币化活动,应予以禁止

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。其中提到,现实世界资产代币化是指使用加密技术及分布式账本或类似技术,将资产的所有权、收益权等转化为代币(通证)或者具有代币(通证)特性的其他权益、债券凭证,并进行发行和交易的活动。在境内开展现实世界资产代币化活动,以及提供有关中介、信息技术服务等,涉嫌非法发售代币票券、擅自公开发行证券、非法经营证券期货业务、非法集资等非法金融活动,应予以禁止;经业务主管部门依法依规同意,依托特定金融基础设施开展的相关业务活动除外。境外单位和个人不得以任何形式非法向境内主体提供现实世界资产代币化相关服务。

49分钟前

央行等八部门:金融机构不得为虚拟货币相关业务活动提供账户开立、资金划转和清算结算等服务

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。其中提到,通知指出,强化对金融、中介、技术等服务机构的管理。金融机构(含非银行支付机构)不得为虚拟货币相关业务活动提供账户开立、资金划转和清算结算等服务,不得发行和销售虚拟货币相关金融产品,不得将虚拟货币及相关金融产品纳入抵质押品范围,不得开展与虚拟货币相关的保险业务或将虚拟货币纳入保险责任范围,并加强风险监测,发现违法违规问题线索应及时向相关部门报告。金融机构(含非银行支付机构)不得为未经同意的现实世界资产代币化相关业务以及相关金融产品提供托管、清算结算等服务。有关中介机构、信息技术服务机构不得为未经同意的现实世界资产代币化相关业务以及相关金融产品提供中介、技术等服务。

49分钟前

央行等八部门:任何单位和个人投资虚拟货币、现实世界资产代币及相关金融产品,损失由其自行承担

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。通知指出,违反本通知规定开展虚拟货币、现实世界资产代币化相关非法金融活动,以及为虚拟货币、现实世界资产代币化相关业务提供服务的,依照有关规定予以处罚;构成犯罪的,依法追究刑事责任。对于明知或应知境外主体非法向境内提供虚拟货币、现实世界资产代币化相关服务,仍为其提供协助的境内单位和个人,依法追究有关责任;构成犯罪的,依法追究刑事责任。任何单位和个人投资虚拟货币、现实世界资产代币及相关金融产品,违背公序良俗的,相关民事法律行为无效,由此引发的损失由其自行承担;涉嫌破坏金融秩序、危害金融安全的,由相关部门依法查处。

49分钟前

中国人民银行、中国证监会有关负责人就《关于进一步防范和处置虚拟货币等相关风险的通知》答记者问

36氪获悉,中国人民银行、中国证监会有关负责人就《关于进一步防范和处置虚拟货币等相关风险的通知》答记者问。关于虚拟货币,长期以来,境内始终对虚拟货币相关业务活动保持禁止性的政策立场。2013年,中国人民银行等五部门联合印发《关于防范比特币风险的通知》,明确比特币是一种特定的虚拟商品,不能且不应作为货币在市场上流通使用。2021年印发的《关于进一步防范和处置虚拟货币交易炒作风险的通知》进一步明确,比特币、以太币,以及泰达币等稳定币,均不具有与法定货币等同的法律地位,在境内开展虚拟货币相关业务活动属于非法金融活动,一律严格禁止。《通知》延续了近年来的政策立场,重申虚拟货币不具有与法定货币等同的法律地位,在境内开展虚拟货币相关业务活动属于非法金融活动,境外单位和个人不得以任何形式非法向境内主体提供虚拟货币相关服务。

49分钟前

分子之心MoleculeOS完成重大代际升级

36氪获悉,近日,分子之心宣布其AI蛋白质优化与设计平台MoleculeOS完成重大代际升级。同时,分子之心依托NewOrigin(达尔文)创新算法,解决了AlphaFold 3等模型无法解决的产业难题。

49分钟前

本页详细列出关于红花牌的品牌信息,含品牌所属公司介绍,红花牌所处行业的品牌地位及优势。
咨询